Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1 drugs linked to significant BMI reduction in children with severe obesity

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year's European Congress on Obesity (ECO 2025) suggests.

12 May 2025

Tirzepatide outperforms semaglutide for weight loss in people without diabetes

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide helped more participants reach key weight loss milestones, with manageable side effects and strong metabolic benefits.

12 May 2025

Tirzepatide outperforms semaglutide in weight loss clinical trial

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.

12 May 2025

GLP-1RAs show added protection against cancer beyond weight reduction

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

11 May 2025

GLP-1 receptor agonists improve mood and metabolic health in adults with mental illness

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on mood, well-being, and quality of life in those both with and without mental illness, according to a systematic review of the available evidence being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May).

11 May 2025

Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic markers, with a favorable safety profile.

4 May 2025

High fructose diets impair brain function and appetite control, study shows

Review highlights how excessive fructose intake disrupts brain energy balance, appetite regulation, and cognitive function. Processed sources, such as sugary drinks, may overwhelm metabolic pathways and induce neuroinflammation, particularly during adolescence.

30 Apr 2025

Semaglutide shows promise in treating severe liver disease

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

30 Apr 2025

Vapourtec video showcases fully automated peptide synthesis

A recent video produced by Vapourtec highlights the patented automatic Variable Bed Flow Reactor (VBFR) demonstrating fully automated solid phase peptide synthesis.

30 Apr 2025

What’s behind Gen Z’s skepticism about Ozempic and Wegovy

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight loss. Concerns focused on safety, social stigma, and a preference for lifestyle changes like diet and exercise.

24 Apr 2025

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.

23 Apr 2025

Monell study offers renewed hope for people living with Bardet-Biedl Syndrome

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments.

18 Apr 2025

Study: Women show greater awareness of obesity drugs than men

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).

17 Apr 2025

GLP1 agonists linked to depression risk in new genetic study

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster drugs like Ozempic-and the risk of depression and suicidal ideation (SI).

17 Apr 2025

New Canadian guidelines offer comprehensive approach to managing pediatric obesity

Researchers provide evidence-based recommendations to manage pediatric obesity.

17 Apr 2025

Comparing single cell RNA methods to improve gastrointestinal cancer research

Research on gastrointestinal diseases, especially cancer, has mainly looked at the epithelial cells, which line the surfaces of organs, are important for various functions, and are believed to be the cells that go awry to cause these diseases.

16 Apr 2025

New findings highlight a shifting landscape for weight loss and glucose managing medications

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

15 Apr 2025

GLP-1 agonists may reshape the gut microbiome

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory benefits for diabetes management.

11 Apr 2025

Study shows minimal lean muscle mass loss with GLP-1 and GLP-1/GIP therapy for weight loss

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment.

9 Apr 2025

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher reporting rate of vision impairment. The findings call for further study into the ocular risks of this widely prescribed diabetes and weight loss drug.

8 Apr 2025